Literature DB >> 21199436

Clinician's guide to prostate IMRT plan assessment and optimisation.

J M Martin1, J Frantzis, T Eade, P Chung.   

Abstract

Intensity-modulated radiotherapy (IMRT) offers dosimetric benefit for irregularly shaped treatment volumes compared to three-dimensional conformal approaches. Some groups advocate IMRT as the standard of care for prostate radiotherapy. For clinicians, assessment of an IMRT plan can introduce new opportunities and challenges. Although a standard IMRT plan may be deemed acceptable by meeting pre-set dose constraints, further optimisation may yield a superior treatment plan by further reducing dose to critical structures or improving target volume homogeneity. The aim of this article is to present aspects of IMRT planning relevant to clinicians to aid in plan critiquing.
© 2010 The Authors. Journal of Medical Imaging and Radiation Oncology © 2010 The Royal Australian and New Zealand College of Radiologists.

Mesh:

Year:  2010        PMID: 21199436     DOI: 10.1111/j.1754-9485.2010.02217.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  6 in total

Review 1.  Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard.

Authors:  Jarad M Martin; Stephane Supiot; Paul J Keall; Charles N Catton
Journal:  Br J Radiol       Date:  2018-01-31       Impact factor: 3.039

2.  Implementation of intensity modulated radiotherapy for prostate cancer in a private radiotherapy service in Mexico.

Authors:  María Adela Poitevin-Chacón; Gabriel Reséndiz González; Adriana Alvarado Zermeño; Jesús Manuel Flores Castro; Christian Haydée Flores Balcázar; Samuel Rosales Pérez; Miguel Angel Pérez Pastenes; Alejandro Rodríguez Laguna; Patricio Vázquez Fernández; Alejandro Calvo Fernández; Jorge Bastida Ventura
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-12

3.  "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.

Authors:  Giulia Marvaso; Giulia Riva; Delia Ciardo; Sara Gandini; Cristiana Fodor; Dario Zerini; Sarah Pia Colangione; Giorgia Timon; Stefania Comi; Raffaella Cambria; Federica Cattani; Ottavio De Cobelli; Roberto Orecchia; Barbara A Jereczek-Fossa
Journal:  Med Oncol       Date:  2018-05-10       Impact factor: 3.064

Review 4.  ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2016-10-20

5.  PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.

Authors:  Matthew Richardson; Mark Sidhom; Sarah Gallagher; Mel Grand; David Pryor; Joseph Bucci; Lee Wilton; Sankar Arumugam; Sarah Keats; Jarad M Martin
Journal:  BMC Cancer       Date:  2018-05-24       Impact factor: 4.430

6.  A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.

Authors:  S Kawakami; H Tsumura; T Satoh; K Tabata; A Sekiguchi; T Kainuma; M Nakano; M Iwamura; H Ishiyama
Journal:  Radiat Oncol       Date:  2022-04-04       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.